A real industry word, but trust-wary drug companies stick to established domains; expect modest, largely defensive registrations.
pharmaceutical and life-sciences companies, B2B suppliers, CROs, pharma-tech startups, recruiters and industry media wanting an industry-labeled address; large drug brands mostly as defensive registrants
One of 46 ICANN 2026-round applications Radix announced on its own applications page. Radix states it intends to build and operate each TLD it wins.
The 2012 applications making the most similar bet. Chosen by AI from every string in that round, without being told what happened to any of them.
Same bet in the same regulated vertical: a sector-category noun whose whole value is being a gated, eligibility-verified namespace where a licensed incumbent moves its primary identity for the trust signal, not a volume registration play.
The canonical restricted-industry noun bet — a small, high-value, verified registrant base of regulated corporations buying legitimacy and anti-counterfeit assurance rather than cheap available inventory, which is exactly the economics .pharma has to run on.
Also an industry shorthand rather than a full entity noun, sitting in the same healthcare-adjacent gray zone where the operator must decide between a professional-eligibility gate and an open generic, with the same ambiguity about whether anyone treats the abbreviation as their primary identity.
- Radix · first recordedRadix
“Radix has applied for these TLDs; we do not own or operate them today.”Radix